Anamorelin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Anamorelin" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

7doi.org

2^nd place

2europa.eu

68^th place

117^th place

1semanticscholar.org

11^th place

8^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Leese PT, Trang JM, Blum RA, de Groot E (March 2015). "An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin". Clinical Pharmacology in Drug Development. 4 (2): 112–120. doi:10.1002/cpdd.175. PMC 4657463. PMID 26640742.
Currow DC, Abernethy AP (April 2014). "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome". Future Oncology. 10 (5): 789–802. doi:10.2217/fon.14.14. PMID 24472001.
Garcia JM, Polvino WJ (June 2009). "Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers". Growth Hormone & IGF Research. 19 (3): 267–73. doi:10.1016/j.ghir.2008.12.003. PMID 19196529.
Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J (January 2015). "Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials". The Lancet. Oncology. 16 (1): 108–16. doi:10.1016/S1470-2045(14)71154-4. PMID 25524795.
Garcia JM, Friend J, Allen S (January 2013). "Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study". Supportive Care in Cancer. 21 (1): 129–37. doi:10.1007/s00520-012-1500-1. PMID 22699302. S2CID 22853697.
Zhang H, Garcia JM (June 2015). "Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC". Expert Opinion on Pharmacotherapy. 16 (8): 1245–53. doi:10.1517/14656566.2015.1041500. PMC 4677053. PMID 25945893.
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (April 2016). "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials". The Lancet. Oncology. 17 (4): 519–531. doi:10.1016/S1470-2045(15)00558-6. PMID 26906526.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Adlumiz". European Medicines Agency. 17 September 2018.
"Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride): Outcome of re-examination" (PDF). European Medicines Agency. 15 September 2017.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Leese PT, Trang JM, Blum RA, de Groot E (March 2015). "An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin". Clinical Pharmacology in Drug Development. 4 (2): 112–120. doi:10.1002/cpdd.175. PMC 4657463. PMID 26640742.
Currow DC, Abernethy AP (April 2014). "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome". Future Oncology. 10 (5): 789–802. doi:10.2217/fon.14.14. PMID 24472001.
Garcia JM, Polvino WJ (June 2009). "Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers". Growth Hormone & IGF Research. 19 (3): 267–73. doi:10.1016/j.ghir.2008.12.003. PMID 19196529.
Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J (January 2015). "Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials". The Lancet. Oncology. 16 (1): 108–16. doi:10.1016/S1470-2045(14)71154-4. PMID 25524795.
Garcia JM, Friend J, Allen S (January 2013). "Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study". Supportive Care in Cancer. 21 (1): 129–37. doi:10.1007/s00520-012-1500-1. PMID 22699302. S2CID 22853697.
Zhang H, Garcia JM (June 2015). "Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC". Expert Opinion on Pharmacotherapy. 16 (8): 1245–53. doi:10.1517/14656566.2015.1041500. PMC 4677053. PMID 25945893.
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (April 2016). "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials". The Lancet. Oncology. 17 (4): 519–531. doi:10.1016/S1470-2045(15)00558-6. PMID 26906526.

ncbi.nlm.nih.gov

Leese PT, Trang JM, Blum RA, de Groot E (March 2015). "An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin". Clinical Pharmacology in Drug Development. 4 (2): 112–120. doi:10.1002/cpdd.175. PMC 4657463. PMID 26640742.
Zhang H, Garcia JM (June 2015). "Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC". Expert Opinion on Pharmacotherapy. 16 (8): 1245–53. doi:10.1517/14656566.2015.1041500. PMC 4677053. PMID 25945893.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Garcia JM, Friend J, Allen S (January 2013). "Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study". Supportive Care in Cancer. 21 (1): 129–37. doi:10.1007/s00520-012-1500-1. PMID 22699302. S2CID 22853697.

Anamorelin (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

europa.eu (Global: 68th place; English: 117th place)